Editas Medicine (EDIT) Non-Current Debt (2016 - 2025)
Editas Medicine (EDIT) posted quarterly Non-Current Debt of $53.6 million for Q4 2025, up 2.23% year-over-year from $52.4 million in Q4 2024, and down 0.86% quarter-over-quarter from $54.1 million in Q3 2025.
Editas Medicine (EDIT) Non-Current Debt (2016 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Non-Current Debt for 4 consecutive years, with $53.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Debt rose 2.23% year-over-year to $53.6 million; the TTM figure through Dec 2025 stood at $53.6 million (up 2.23% YoY), while the FY2025 annual figure was $53.6 million, up 2.23% from the prior year.
- Non-Current Debt eased to $53.6 million in Q4 2025 per EDIT's latest filing, from $54.1 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $54.1 million in Q3 2025 and bottomed at $49.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | 53.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 53.61 Mn |
| Sep 30, 2025 | 54.07 Mn |
| Jun 30, 2025 | 51.67 Mn |
| Mar 31, 2025 | 49.58 Mn |
| Dec 31, 2024 | 52.43 Mn |
| Dec 31, 2017 | 7.50 Mn |
| Jun 30, 2017 | 15.00 Mn |
| Mar 31, 2017 | 15.00 Mn |
| Dec 31, 2016 | 10.00 Mn |